Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

10 results about "Allergic contact dermatitis" patented technology

Allergic contact dermatitis (ACD) is a form of contact dermatitis that is the manifestation of an allergic response caused by contact with a substance; the other type being irritant contact dermatitis (ICD).

IBS related testing and treatment

PendingUS20250235148A1SurgeryVaccination/ovulation diagnosticsSkin patch testAllergic contact dermatitis
Methods and items useful at least therein are provided for IBS related testing and treatment. Disclosed is a patch useful in determining if one or more test materials can cause allergic contact dermatitis in a patient. A kit containing information on use and that may include such a patch and / or test material(s) is also disclosed. A method of IBS related testing including performing skin patch testing on a patient presenting IBS symptoms using at least one test material that can cause allergic contact dermatitis is provided. A method for the treatment of IBS which includes limiting the intake by a patient presenting IBS symptoms of at least one material that gives a positive skin patch test result in the patient is also disclosed.
Owner:IBS 80 LLC

External traditional Chinese medicine compound temperature-sensitive slow-release hydrogel as well as preparation method and application thereof

The invention discloses external traditional Chinese medicine compound temperature-sensitive slow-release hydrogel as well as a preparation method and application thereof. The preparation method comprises the following steps: uniformly mixing a hyaluronic acid aqueous solution and a chitosan quaternary ammonium salt aqueous solution, centrifuging to take supernate, and freeze-drying to obtain a hyaluronic acid / chitosan quaternary ammonium salt microgel freeze-dried substance; and uniformly mixing the hyaluronic acid / chitosan quaternary ammonium salt microgel freeze-dried substance, the traditional Chinese medicine compound water extract freeze-dried powder, a temperature-sensitive material and water to obtain the external traditional Chinese medicine compound temperature-sensitive slow-release hydrogel. The traditional Chinese medicine compound preparation can be quickly converted into a gel state from a solution state when being in contact with the skin of a patient, the traditional Chinese medicine compound preparation covers an affected part and is not easy to fall off, and the sustained-release hydrogel has the unique advantages of prolonging the administration time, reducing the administration frequency, reducing adverse reactions and being easily accepted by the patient, can be used for relieving allergic contact dermatitis non-histamine-dependent itching, and has a good application prospect. Wide clinical application prospects are realized.
Owner:GUANGZHOU SAI ANSI BIOTECHNOLOGY CO LTD

Use of tyramine for the preparation of a medicament for the prevention and / or treatment of contact dermatitis

PendingCN123078465AContact dermatitisAcropustulosis
This invention provides the application of tyramine in the preparation of drugs for the prevention and / or treatment of contact dermatitis, belonging to the field of biomedical technology. This invention addresses the treatment challenges of contact dermatitis patients, such as difficulty in avoiding allergens, frequent relapses, and limited choices of topical medications. Through animal experiments, this invention has found that topical application of tyramine can alleviate skin inflammation in a mouse model of recurrent allergic contact dermatitis induced by DNFB, and significantly reduce inflammatory cells, especially CD8+, in the skin lesions. + T cell infiltration was significantly reduced; and further research revealed that after the initial inflammation, skin CD8... + The long-term survival of tissue-resident memory T cells was significantly inhibited, and tyramine is expected to become a therapeutic drug for allergic contact dermatitis, providing a new approach for the clinical treatment and prevention of recurrence of allergic contact dermatitis.
Owner:SHANGHAI DERMATOLOGY HOSPITAL

An artemisia leaf water extract, a preparation method thereof, and application of the artemisia leaf water extract in preparing a medicine for treating allergic contact dermatitis

PendingCN122351321AFreeze-dryingEfficacy
This invention discloses a method for preparing an aqueous extract of Artemisia argyi and its application, particularly in the preparation of drugs for treating allergic contact dermatitis. The preparation method includes step 1: naturally air-drying harvested Artemisia argyi leaves, followed by mechanical pulverization to obtain Artemisia floss raw material; step 2: mixing the Artemisia floss raw material with pure water, soaking at room temperature, extracting with ultrasound assistance, combining the extracts, decocting in a water bath, concentrating under reduced pressure, and freeze-drying to obtain the Artemisia argyi aqueous extract. This invention provides an Artemisia argyi aqueous extract, its preparation method, and its application. This Artemisia argyi aqueous extract has significant anti-allergic and anti-irritant effects, effectively inhibiting hyaluronidase activity, reducing erythrocyte hemolysis rate, and exhibiting good therapeutic effects on 2,4-dinitrofluorobenzene-induced allergic contact dermatitis. It also has high bioavailability and good safety. This invention lays an important foundation for developing efficient and safe natural anti-allergic products.
Owner:SHANGHAI NORMAL UNIVERSITY +1

Application of secretory glucose regulatory protein 78 in preparation of medicine for treating allergic contact dermatitis

The invention belongs to the technical field of biological medicines, discloses an application of secreting type glucose regulatory protein 78 in preparation of a medicine for treating allergic contact dermatitis, and proves that the secreting type Grp78 protein reduces inflammatory reaction by inducing macrophage M2 polarization and reducing expression of cytokines IL-6, INF-gamma and TNF-alpha, so that symptoms of ACD are improved, and the application of the secreting type Grp78 protein in preparation of the medicine for treating allergic contact dermatitis is promoted. And a new theoretical basis and a new technical method are provided for treatment of ACD and exploration of novel drugs.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH

Use of neuroprotectin d1 (NPD1) in the manufacture of a medicament for alleviating / treating chronic pruritus

This application discloses the use of neuroprotective agent D1 (NPD1) in the preparation of drugs to relieve / treat chronic pruritus, relating to the field of biomedical technology. This invention provides NPD1 that can reverse spinal cord demyelination and relieve chronic pruritus. NPD1 can be used to relieve and / or treat chronic dermatitis pruritus, particularly showing excellent inhibitory effects against allergic contact dermatitis. The NPD1 can be developed into conventional lipid nanoparticles (LNPs) or other similar lipid nanoparticle drug formulations for drug delivery, possessing significant potential application value for relieving itching. The NPD1 developed in this invention can directly relieve pruritus abnormalities caused by dorsal horn demyelination of the mouse spinal cord, fundamentally inhibiting the occurrence of pruritus abnormalities in chronic dermatitis, solving the clinical problem of chronic pruritus that plagues patients with chronic dermatitis, and providing a new and effective solution for the clinical treatment of chronic dermatitis, especially pruritus in allergic contact dermatitis.
Owner:NANTONG UNIV

Pharmaceutical composition for treating damp-heat accumulation type allergic contact dermatitis and preparation method and application thereof

The invention provides application of a pharmaceutical composition to preparation of an external medicine for treating allergic contact dermatitis, wherein the pharmaceutical composition is prepared from the following raw material medicines in parts by weight: 25-35 parts of purslane, 25-35 parts of fructus cnidii, 15-25 parts of fructus kochiae, 15-25 parts of nidus vespae, 5-15 parts of cortex dictamni, 5-15 parts of pepper, 10-20 parts of rheum officinale and 10-20 parts of senecio scandens. The invention also provides a preparation method of the pharmaceutical composition. The composition has the effects of clearing heat and drying dampness, cooling blood and diminishing swelling, and dispelling wind and arresting itching, is externally washed on an affected part, effective components directly reach the affected part after being absorbed by skin, has the characteristics of direct action, quick response, convenience and simplicity, small toxic and side effects and the like, has the effects of clearing heat and drying dampness, cooling blood and diminishing swelling, and dispelling wind and arresting itching together, and has a remarkable effect on treating the allergic contact dermatitis.
Owner:TEACHING HOSPITAL OF CHENGDU UNIV OF T C M

Application of traditional Chinese medicine composition in preparation of medicine for treating allergic contact dermatitis

The invention relates to an application of a traditional Chinese medicine composition in preparing a medicine for treating allergic contact dermatitis, which is characterized in that the traditional Chinese medicine composition is prepared from astragalus membranaceus, dried ginger, salted morinda officinalis, cortex dictamni, calcined oyster shell, schisandra chinensis and divaricate saposhnikovia root. The composition disclosed by the invention can be used for remarkably inhibiting ear swelling of allergic contact model mice, remarkably reducing the content of IL-5 and IL-9 in ear tissues of the model mice and remarkably reducing the spleen index of the model mice, and has a relatively good treatment effect on the allergic contact dermatitis.
Owner:JIANGSU KANION PHARMA CO LTD

Application of Artemisia argyi essential oil as a TRPA1 pathway inhibitor in anti-inflammatory and antipruritic drugs

ActiveCN115944662BReduce spontaneous scratchingReduce epidermal thickeningAntipyreticAnalgesicsMugwortPharmaceutical drug
The present invention relates to the technical field of traditional Chinese medicine, and specifically discloses the application of wormwood volatile oil as a TRPA1 pathway inhibitor in anti-inflammatory and antipruritic drugs. The wormwood volatile oil provided by the present invention can downregulate MAPK and JAK / STAT3 signaling pathways, inhibit the expression levels of inflammatory cytokines TNF-α, IL-1β, IL-6, IL-33 and IL-4, inhibit the expression of p-p38, p-ERK1 / 2 and p-STAT3 proteins, and then exert anti-inflammatory and antipruritic effects. The anti-inflammatory and antipruritic effects of the wormwood volatile oil were verified in a SADBE-induced mouse allergic contact dermatitis itch model.
Owner:SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES

Prefilled cutaneous patch with landmark

A prefilled cutaneous patch is provided for testing for allergic contact dermatitis and / or skin sensitivity. The patch comprises one or more wells containing ingredients that may be mixed with a suitable base (e.g., petrolatum, an aqueous solution, an anhydrous compound). The patch further comprises a backing that features an adhesive surface for adhering to a user's skin, and one or more landmarks that facilitate marking of the skin to visually demonstrate an orientation of the applied patch (e.g., which end is up, locations of wells). A landmark may comprise a dye or ink, which may be installed in one or more wells or elsewhere on the patch such that it is transferred to the user's skin when the patch is applied. Also, or alternatively, a landmark may comprise a stencil through which the user may mark the skin with a pattern that promotes interpretation of the results of the testing.
Owner:ALL SKIN INC